难治性药疹伴嗜酸性粒细胞增多和系统症状综合征中CCR8/CCL1与CXCR3/CXCL10轴介导的记忆T细胞活化
BACKGROUND: As a drug-induced hypersensitivity syndrome, drug reaction with eosinophilia and systemic symptoms (DRESS) is potentially fatal.…
要点
- 难治性DRESS急性期血CCR8和CXCR3 mRNA表达显著高于健康对照。
- 难治性DRESS血清和皮损CCL1、CXCL10水平显著高于短疗程DRESS。
- JAK抑制剂(托法替布、乌帕替尼)可降低CCL1和CXCL10释放。
核心结论
- JAK抑制剂(托法替布和乌帕替尼)与CCL1和CXCL10浓度降低相关,可能减弱CCR8/CCL1和CXCR3/CXCL10轴介导的记忆T细胞活化,该活化参与难治性长疗程DRESS的发病。
主要发现
- 难治性DRESS急性期血CCR8 mRNA表达较健康对照显著升高,Padj=1.50×10-9。
- 难治性DRESS急性期血CXCR3 mRNA表达较健康对照显著升高,Padj=2.60×10-4。
- 难治性DRESS患者血清和皮损CCL1和CXCL10浓度显著高于短疗程DRESS患者。
- 难治性DRESS患者CD8+ GNLY+ CXCR3+效应记忆T细胞、CD8+中央记忆T细胞、CD4+ CCR8+ Th2细胞及IgG抗HES-6自身抗体显著增加。
- 体外阻断实验中JAK抑制剂(主要为托法替布和乌帕替尼)显著降低CCL1和CXCL10释放。
关键数值与推荐
- 难治性DRESS定义为疗程≥8周,短疗程DRESS定义为疗程<2周。
- 部分难治性DRESS患者经JAK抑制剂治疗成功。
临床怎么用
- 对于疗程迁延的难治性DRESS患者,可考虑JAK抑制剂(托法替布、乌帕替尼)治疗以降低CCL1和CXCL10水平。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: As a drug-induced hypersensitivity syndrome, drug reaction with eosinophilia and systemic symptoms (DRESS) is potentially fatal. Most patients with DRESS recover within a few weeks; however, some patients may suffer from a prolonged disease course and develop autoimmune sequelae. OBJECTIVES: To investigate the immune mechanism and therapeutic targets of patients with recalcitrant DRESS with a prolonged disease course. METHODS: Thirty-two patients with recalcitrant DRESS with a prolonged treatment course (≥ 8 weeks; 'prolonged DRESS'), 28 patients with DRESS with a short treatment course (< 2 weeks; 'short-duration DRESS') and 26 healthy donors (HDs) were enrolled. RESULTS: Bulk transcriptome results showed that the mRNA expression levels of CCR8 and CXCR3 were significantly increased in blood samples from patients in the acute stage of prolonged DRESS [Padj = 1.50 × 10-9 (CCR8) and Padj = 2.60 × 10-4 (CXCR3), patients with prolonged DRESS compared with the HD group]. Serum and skin lesion concentrations of CCL1 and CXCL10 (ligands of CCR8 and CXCR3, respectively) were significantly increased in patients with prolonged DRESS compared with patients with short-duration DRESS. The results from high-parameter flow cytometry and autoantibody screening also identified significant increases in CD8+ GNLY+ CXCR3+ effector memory T cells, CD8+ central memory T cells, CD4+ CCR8+ T helper 2 cells and IgG anti-HES-6 autoantibodies in patients with prolonged DRESS. Furthermore, in vitro blocking assays revealed that Janus kinase inhibitors (JAKi; mainly tofacitinib and upadacitinib) significantly decreased the release of CCL1 and CXCL10. Some patients with prolonged DRESS were successfully treated with JAKi. CONCLUSIONS: JAKi (tofacitinib and upadacitinib) were associated with decreased concentrations of CCL1 and CXCL10, suggesting that they may attenuate CCR8/CCL1 and CXCR3/CXCL10 axis-mediated memory T-cell activation, which contributes to disease pathogenesis in patients with recalcitrant DRESS and a long-term treatment course. Drug-induced hypersensitivity syndrome is a severe reaction to medication. Most people get better in a few weeks, but some may take longer to recover. This study looked at how the immune system works in people with this syndrome who needed treatment for longer. Higher levels of proteins that can trigger skin inflammation were found in these patients. Treatment with drugs called ‘JAK inhibitors’ blocked the release of proteins called CCL1 and CXCL10. We found that some people with drug-induced hypersensitivity who needed longer treatment were successfully treated with these drugs. JAK inhibitors may help lower the activation of certain immune responses. This could help control drug-induced hypersensitivity in people who need long-term treatment.
引用
- Chiu TM, Chen CB, Lu CW, et al. CCR8/CCL1 and CXCR3/CXCL10 axis-mediated memory T-cell activation in patients with recalcitrant drug-induced hypersensitivity. Br J Dermatol. 2025. PMID: 39503255. doi:10.1093/bjd/ljae375
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。